Tenderwize
Back to tender search

Clinical Trial Readiness through the Establishment of a Pilot Filovirus Investigational Vaccine Reserve

Health and Digital Executive Agency (HaDEA)·Brussels, Belgium·EUR 16M·Deadline Aug 25, 2026 · 24 days left·Open·Services
High valueStructured notice only
Original notice title

Belgium – Research and experimental development services – Clinical Trial Readiness through the Establishment of a Pilot Filovirus Investigational Vaccine Reserve

70/100

Opportunity Score

Needs reviewMedium complexity
ServicesOpen
Why this score?

Opportunity

70 / 100

Complexity

65 / 100

Risk factors

Rapid deployment of investigational vaccines during outbreaks requires pre-established logistics, regulatory approvals...

Investigational vaccines are subject to evolving EU and international regulations. Changes in clinical trial or manufac...

Deep Portfolio Analysis

Deep Company Fit Analysis

Uses:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Overview

Moderate opportunity

Key Facts

  • EUR 16M estimated value
  • Services contract
  • 1 lot
  • Duration 48 MONTH
  • Establish and maintain a reserve of investigational Filovirus vaccines (Ebola Sudan, Ebola Bundibugyo, Marburg) in the EU.
  • Ensure rapid deployment of investigational doses during outbreaks subject to conditions.
Show full summary

This open tender by the Health and Digital Executive Agency (HaDEA) seeks to establish a pilot EU-based reserve of investigational Filovirus vaccines (against Ebola Sudan, Ebola Bundibugyo, and Marburg) to ensure clinical trial preparedness. The contract involves maintaining and rapidly deploying candidate vaccines during outbreaks. The single lot has an estimated value of €16,000,000 (EU-funded) and a duration of 48 months. Award is based on quality (80%) and price (20%). Submission deadline is 25 August 2026. Key documents and eligibility details are not specified in the provided data.

Risks

Rapid deployment of investigational vaccines during outbreaks requires pre-established logistics, regulatory approvals...

Investigational vaccines are subject to evolving EU and international regulations. Changes in clinical trial or manufac...

Analysis may be incomplete

Only part of the procurement documentation was analyzed. Additional eligibility requirements, certificates, or submission documents may exist in the remaining tender documentation.

Key Requirements

Technical

  • Tenderers must have the capability to manufacture, store, and maintain investigational vaccines under appropriate conditions.
  • Rapid deployment mechanism must be in place for outbreak scenarios.
  • Compliance with EU regulations and funding requirements (EU4Health programme).

Requirements may be incomplete.

Award Criteria

Lot 1

Quality criterion weighted at 80%80%Price criterion weighted at 20%20%

Buyer

Location

Brussels, BEL

Identifier

HADEA

Activity

General public services

Lots (1)

LOT-0001

Clinical Trial Readiness through the Establishment of a Pilot Filovirus Investigational Vaccine Reserve

This lot covers the establishment, piloting, and maintenance of an investigational reserve of Filovirus candidate vaccines (SUDV, BDBV, MARV) for rapid deployment in outbreak-associated clinical trials. Tenderers must ensure rapid deployment under specific conditions (outbreak occurrence and HAEA consent).

ServicesEU fundedElectronic submission

EUR 16M

Estimated value

Duration

48 MONTH

Category

Research

Award Criteria

Best price-quality ratio

Deadline

Deadline Aug 25, 2026

Procurement Details

Publication date
02 Jun 2026
Languages
English, Bulgarian

Reference metadata

Legal basis
32024R2509

Reference IDs

Tender ID
381062-2026

Documents (2)

Similar tenders